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Abstract
Background: Alternative splicing (AS) is a central mechanism in the generation of genomic complexity and is a
major contributor to transcriptome and proteome diversity. Alterations of the splicing process can lead to
deregulation of crucial cellular processes and have been associated with a large spectrum of human diseases.
Cancer-associated transcripts are potential molecular markers and may contribute to the development of more
accurate diagnostic and prognostic methods and also serve as therapeutic targets. Alternative splicing-enriched
cDNA libraries have been used to explore the variability generated by alternative splicing. In this study, by
combining the use of trapping heteroduplexes and RNA amplification, we developed a powerful approach that
enables transcriptome-wide exploration of the AS repertoire for identifying AS variants associated with breast
tumor cells modulated by ERBB2 (HER-2/neu) oncogene expression.
Results: The human breast cell line (C5.2) and a pool of 5 ERBB2 over-expressing breast tumor samples were used
independently for the construction of two AS-enriched libraries. In total, 2,048 partial cDNA sequences were
obtained, revealing 214 alternative splicing sequence-enriched tags (ASSETs). A subset with 79 multiple exon
ASSETs was compared to public databases and reported 138 different AS events. A high success rate of RT-PCR
validation (94.5%) was obtained, and 2 novel AS events were identified. The influence of ERBB2-mediated
expression on AS regulation was evaluated by capillary electrophoresis and probe-ligation approaches in two
mammary cell lines (Hb4a and C5.2) expressing different levels of ERBB2. The relative expression balance between
AS variants from 3 genes was differentially modulated by ERBB2 in this model system.
Conclusions: In this study, we presented a method for exploring AS from any RNA source in a transcriptome-wide
format, which can be directly easily adapted to next generation sequencers. We identified AS transcripts that were
differently modulated by ERBB2-mediated expression and that can be tested as molecular markers for breast
cancer. Such a methodology will be useful for completely deciphering the cancer cell transcriptome diversity
resulting from AS and for finding more precise molecular markers.
Background
More than 30 years ago, Gilbert predicted the exis-
tence of protein variants due to the alternative use of
exon-intron borders in eukaryotic cells [1]. This pre-
diction has been continually confirmed as a common
feature of many species, including humans. Recent
estimations, based on high-throughput sequencing,
suggest that 90-95% of multiple-exon human genes
undergo alternative splicing (AS) [2,3], producing an
average of six distinct transcripts from each gene [4].
This phenomenon enormously impacts the repertoire
of proteins, since 80% of AS events occur within the
coding region [5], thus interfering in the functional
aspects of the cells.
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development, cellular differentiation and apoptosis, by
the generation of different protein isoforms among dis-
tinct tissues, developmental stages and pathological con-
ditions [6-8]. Alterations of the splicing process, such as
the loss of expression balance between variants and
aberrant splicing, can lead to the deregulation of crucial
cellular processes and are consequently associated with
a large spectrum of human diseases [9], including cancer
[10-12].
The development of methodologies to explore tran-
scriptome diversity resulting from AS has been shown
to be a potent tool, not only for improving the biologi-
cal basis of cancer but also for searching for more pre-
cise molecular markers for diagnostic, prognostic and
therapeutic purposes [13,14]. Different strategies for
large-scale AS variant exploration have been used with
different goals. Sequence and microarray-based
approaches have been used for defining the AS reper-
toire of human cells. The former includes several com-
putational analyses concerning genomic and
transcriptome alignments of human ESTs (expressed
sequence tags) and mRNA databases [11,15-17] and
cross-species alignment from closely related organisms
[18,19]; the latter includes genomic and exon-intron
junction microarray platforms [20-23]. Both approaches
have contributed to the investigation of the expression
pattern of AS variants and also facilitated the identifica-
tion of novel AS variants. Nonetheless, both approaches
are impaired in detecting low-abundance AS transcripts.
In this sense, AS-enriched cDNA libraries is one of the
most interesting approaches because it combines the
convenience of cDNA direct sequencing with the advan-
tage of detecting low-abundance transcript variants. The
methodology is based on one enrichment step, consist-
ing of the trapping of heteroduplex molecules formed
by the hybridization of two distinct AS variants from
the same gene [24]. The heteroduplex can be captured
by molecules that recognize the heteroduplex structure
[25,26], generating a vast number of AS events without
previous knowledge of them. In this study, to explore
AS variants associated with breast tumor cells, we estab-
lished a powerful approach that enabled the direct
exploration of an AS repertoire by combining the use of
trapping heteroduplex and RNA amplification. To favor
the trapping of splicing variants associated with breast
tumor cells that over-expresses the ERBB2 (HER-2/neu)
oncogene, a human breast cell line (C5.2) and a pool of
5 ERBB2 over-expressing breast tumor samples were
used. Two AS-enriched libraries were constructed, gen-
erating a set of 2,048 partial cDNA sequences, named
here as alternative splicing sequence-enriched tags
(ASSETs), as suggested by Watahiki and collaborators
[25]. A subset with 79 ASSETS representing distinct
multiple exon sequences was explored in this analysis
and reported 138 different AS events. A high rate of
validation by RT-PCR (94.5%) was obtained, and 2 novel
AS events were identified. Moreover, the balance in the
expression level of the AS variants from 3 genes was
influenced by ERBB2-mediated expression.
The approach presented here certainly will contribute
to the identification of the AS repertoire of cancer cells,
especially as it is potentially applicable to any cell type
from any tumor tissue, since a small amount of total
R N Ai sr e q u i r e dw i t hn op r e v i o u sc D N Al i b r a r yc o n -
struction. Furthermore, it is completely suitable for
using with next-generation sequencers, substantially
increasing its potential in deciphering the AS diversity
in cancer cell transcriptome.
Results
Alternative splicing libraries
Two distinct AS libraries were constructed (Lib_1 and
Lib_2) using 5 µg of total RNA as the starting material.
Library 1 (Lib_1) was prepared from the human breast
cell line C5.2, which over-expresses the oncogene
ERBB2, and library 2 (Lib_2) was prepared from a pool
of 5 invasive breast carcinoma samples that stained posi-
tively for ERBB2 according to immunohistochemistry
analysis (Table 1).
The strategy for AS library construction was based on
the methodology described by Watahiki and collabora-
tors [25] with some modifications. One significant dif-
ference was the use of total RNA instead of parental
full-length cDNA libraries, which simplifies the process
and decreases costs. Another important adaptation was
the inclusion of a RNA amplification procedure based
on T7 RNA polymerase and Template Switch oligo (TS-
oligo) [27], which allows the use of small quantities of
RNA (Figure 1 I-IV). The amplified RNA was converted
into double-stranded cDNA (dscDNA) (Figure 1 V-VI),
which was then submitted to denaturation and renatura-
tion steps, promoting the formation of heteroduplex
DNA molecules by the hybridization of complementary
regions from two distinct splicing variants from the
same gene (Figure 1 VII). The remaining single-stranded
molecules or overhanging regions were removed with
exonuclease VII treatment (Figure 1 VIII), whereas the
double-stranded cDNA molecules were cleaved with the
DpnII restriction enzyme (Figure 1 IX). This step
resulted in double-stranded fragments, constituting
homo- and heteroduplex molecules with cohesive ends
to bind adaptors. The enrichment of the heteroduplex
molecules occurred through the trapping of single-
stranded loops by the annealing of random 25-mer
biotinilated oligonucleotides captured by streptavidin
magnetic particles (Figure 1 X). Complementary over-
hanging adaptors were then specifically ligated to the
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XI), generating a recognition site for primer annealing
and consequently allowing for PCR amplification (Figure
1 XII), cloning and sequencing.
A total of 2,048 high quality sequences (Phrep > 20)
were generated from both libraries. Sequences from
each library were clustered using the CAP3 program
[28], resulting in 149 consensus sequences for library
Lib_1 (96 contigs and 53 singlets) and 146 consensus
sequences for library Lib_2 (74 contigs and 74 singlets)
(Table 2 and Figure 2A). The number of consensus
sequences obtained revealed, as expected, a high redun-
dancy within the libraries (Table 2), since no normaliza-
tion procedure was implemented in our approach.
All consensus sequences were then aligned to the
human genome (NCBI build #36.1) using BLAST [29]
and Sim4 [30], where only the best hit was considered.
Based on criteria for identity (≥ 93%) and coverage (≥
55%), 214 consensus sequences were aligned on the
human genome, 93 and 121 of them reporting multiple
and one-exon(s) sequences, respectively (Figure 2B). The
consensuses were termed ASSETs, as previously pro-
posed [25,26].
Furthermore, to check whether our library construc-
tion approach enables full-length representation, includ-
ing the 5’ end of transcripts, we verified the relative
position of the ASSETs throughout the length of full-
lengths (Figure 3). The analysis resulted in a similar
representation of 3’ and 5’ ends with a slightly higher
concentration of ASSETs in the central region, indicat-
ing that no bias were introduced towards higher repre-
sentation of full transcript 3’ ends. Additionally, the fact
that the average size of mRNAs (RefSeq) represented by
ASSETs in our libraries was of 2,836 nt, similar to the
average size of all mRNA sequences from RefSeq
Table 1 Clinical characteristics from the ductal carcinoma samples
Sample Name Stage Age TNM LN Grade Molecular Markers
9T IIa 55 years T2N0M0 Negative Grade I SBR ER +/ PR +/ p53 -/ ERBB2+ (3+)
20T IIb 87 years T2N0M0 Negative Grade II SBR ER +/ PR -/ p53 -/ ERBB2+ (3+)
22T IIb 56 years T2N1M0 Positive Grade III SBR ER +/ PR -/ p53 -/ ERBB2+ (2+/3+)
28T IIIa 42 years T2N2M0 Positive Grade II SBR ER +/ PR -/ p53 -/ ERBB2+ (3+)
36T I 45 years T1N0M0 Negative Grade III SBR ER +/ PR -/ p53 -/ ERBB2+ (3+)
Age: age of diagnosis; TNM: classification according to TNM (T – size; N – lymph node status; M – presence of metastasis); LN: involvement of sentinel lymph
nodes; grade: grades I, II and III according to SBR; molecular markers: ER – estrogen receptor; PR – progesterone receptor; p53 – protein TP53; and ERBB2 –
protein ERBB2.
Figure 1 Schematic view of the alternative splicing library
construction with amplification of RNA. I. Oligo dT containing T7
RNA Polymerase recognition site was used for first strand cDNA
synthesis with Superscript II that adds cytosine residues after
reaching the 5`end of mRNAs. II. This c-rich region serves as anchor
for TS-oligo alignment, allowing further polymerization to the end
of the oligo. III. Second strand cDNA synthesis using TS-oligo. IV.
Amplification of mRNA using T7 RNA Polymerase. V. First strand
cDNA synthesis using TS-oligo. VI. Second strand cDNA synthesis
using oligodT. VII. Denaturation and renaturation resulting in the
formation of heteroduplexes molecules by common exons
complementarity. VIII. Single-stranded molecules degraded by
Exonuclease (dotted line). IX. DpnII digestion resulting in small
cohesive fragments. X. 25mer biotinilated random oligos coupled to
streptavidin magnetic beads anneal to single-strand loops. XI.
Coupling of specific adaptors to the cohesive ends of the captured
heteroduplexes. XII. PCR amplification of fragments using adaptors
specific oligos (double line).
Table 2 Characterization of libraries Lib_1 and Lib_2
Library # High Quality
Sequences
#
Contigs
#
Singlets
#
Consensus
Redundancy
Lib_1 946 96 48 144 84.78%
Lib_2 1102 74 71 145 86.84%
Total 2048 170 119 289 -
Ferreira et al. BMC Genomics 2010, 11(Suppl 5):S4
http://www.biomedcentral.com/1471-2164/11/S5/S4
Page 3 of 15database (3,098 nt) suggested no bias in representation
of 5’ end from short transcripts (Figure 3).
Detection of alternative splicing events
No distinct splicing variants were observed among the
sequences belonging to the same consensuses that
would be indicative of putative AS events. Therefore, we
searched for AS events through comparisons between
ASSETs and full-length or partial cDNA sequences
available in public databases.
First, ASSETs were clustered with ESTs from dbEST
(8,133,299 ESTs), mRNAs (244,284 sequences) and
RefSeqs (26,040 sequences) downloaded from UCSC
(September 2007) (Figure 2C). This step resulted in 164
clusters, where 142 contained at least one RefSeq
sequence. Sixteen clusters contained sequences from
both libraries (Lib_1 and Lib_2), revealing an overlap of
approximately 10%.
The 79 clusters containing ASSETs with multiple
exons were scanned for AS events through pairwise
comparisons of exon/intron boundaries between the
ASSET and the reference sequences of each cluster. AS
events were searched within the region delimited by the
two outermost overlapping regions of each ASSET
related cluster. For each ASSET, the corresponding gene
and the number and type of related alternative splicing
events were annotated.
All 79 multiple exon ASSETs were considered known
transcripts since they were represented by sequences at
public databases. Moreover, for 39 out of 79 ASSETs
(49.4%), an alternatively spliced transcript was described
in the public databases. For these 39 ASSETs, 138 AS
events were detected, including intron retention (5.8%),
exon skipping (9.4%), alternative splice site 3’ (39.8%)
and alternative splice site 5’ (44.9%). The remaining 40
ASSETs, to which no AS event has been reported, may
result from novel AS events not yet reported in public
databases (Table 3). The intronless ASSETs were not
used for the AS search, since it is not possible to iden-
tify the direction of transcripts in the absence of splice
sites. Nonetheless, it is interesting to note that 63 out of
96 intronless sequences (65.6%) aligned to regions
involved in AS, according to public databases. This can
be considered an indirect sign that these ASSETS are
prone AS transcripts.
Gene ontology annotation
For exploring the functional aspects of the genes that
harbor AS, the 142 ASSETs were classified within the
biological process categories. Using BinGO tools [31],
11 categories revealed a statistically significant enrich-
ment of genes (Table 4) and are represented in a hier-
archical form in Figure 4. The most significantly
enriched category was translation elongation, due to a
great number of ribosomal proteins detected in our
data.
Validation of ASSETs and heteroduplexes
Eighteen ASSETs were randomly selected for RT-PCR
validation, including 6 and 7 ASSETs exclusively from
Lib_1 and Lib_2, respectively and 5 ASSETs that were
detected in both libraries. The validation process was
performed in two steps: i. ASSET validation - to confirm
the presence of the ASSET in the same RNA used for
library construction and ii. heteroduplex validation - to
search for alternatively spliced transcripts that could
have participated in the heteroduplex formation (Table
5). By using a pair of primers that aligned at the extre-
mities of the ASSET sequence, all but one ASSET was
validated (17 out of 18, 94.4% validation rate). The 5
ASSETs identified by both libraries were validated in
both templates. Secondly, for 6 (SFRS9, FLNA,
ALDH3A2, PTPLA, RPS2 and TRIP6) out of the 17 vali-
dated ASSETs (35.3%), an additional AS variant was
identified that could have participated in the heterodu-
plex formation. Two out of 6 AS variants that were
transcribed from the genes PTPLA and TRIP6, which
Figure 2 Flowchart of the bioinformatics pipeline.
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cing variants. The lack of heteroduplex validation for
the other 11 genes was probably due to a differential
expression balance between splicing variants that pre-
cluded the amplification of one variant in favor of the
most abundant one. The support for this assumption is
t h a tf o r5o u to f1 1( 4 5 . 5 % )g e n e s ,a nA Sv a r i a n tt h a t
could have participated in the heteroduplex formation
was available in databases. For verifying whether the low
level of overlap between both libraries was due to the
low coverage in terms of the number of sequences gen-
erated for each library or due to the specific AS pattern
of each RNA source used, we tested if the 13 ASSETs
validated in cDNA from the corresponding library were
also expressed in the cDNA from the other library. Four
ASSETs from the 5 identified by Lib_1 were successfully
amplified using the cDNA from the pool of the tumor
samples (Lib_2). All 7 ASSETs from Lib_2 were success-
fully amplified using the cDNA from C5.2 (Lib_1), total-
ing 91.8% cross-validation (11 out of 12). The validation
results are summarized in Table 5.
Novel alternative splicing: characterization of the putative
isoforms
The 2 novel AS variants were characterized regarding
the putative corresponding protein isoform. The PTPLA
gene [RefSeq:NM_014241.3] codes for the member A of
the protein tyrosine phosphatase-like family that con-
tains proline instead of catalytic arginine. This gene con-
tains 7 exons, and the AS variant detected in our study
is due to the use of an alternative 5’ splice site of intron
5 that elongates exon 5 by 117 nt (Figure 5A). All pro-
tein functional domains found for PTPLA were also pre-
sent in the novel AS detected. However, in the novel AS
variant, a premature stop codon was created 96 nt
upstream of the exon 5/exon 6 junction, probably lead-
ing to regulation by non-sense mediated decay (NMD)
[32,33].
The TRIP6 gene [RefSeq:NM_003302.2] is a thyroid
hormone receptor interactor 6 that contains 9 exons.
The novel alternatively spliced transcript reports reten-
tion of the last intron (Figure 5B). The protein coded by
the TRIP6 gene localizes to focal adhesion sites and
along actin stress fibers. The novel AS variant identified
also inserts a premature stop codon in the putative cod-
ing protein, without interfering with any protein func-
tional domain.
Evaluation of AS variant regulation by ERBB2-mediated
expression
Finally, we investigated the putative influence of ERBB2-
mediated expression on the regulation of AS variants for
17 ASSETS validated using GAPDH as a normalization
factor, by comparing the expression level of the ASSETs
in the C5.2 cell line in relation to the ERBB2 basal
expressed counterpart – the normal breast cell line
(Hb4a) through capillary microfluidic electrophoresis
(LabChip GX – Caliper Lifesciences) that accurately
assesses the size and quantity of each amplification
product [34].
Figure 3 Relative position of the ASSETs throughout full-length mRNAs. The graphic represents the distribution of the ASSETs along
corresponding transcript position. In the x-axis the relative transcript position is shown as a percentage value, where 0 indicates the 5’ end and
100 indicates the 3’ end. The coverage is the number of ASSETs aligning at each position.
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levels were analyzed showing a slight influence of
ERBB2 over-expression in all ASSETs (ratio ranging
from -1.9 to 1.4) (Supplemental Table 1).
For the 6 ASSETS presenting an additional AS variant,
t h ep u t a t i v ei n f l u e n c eo fERBB2 over-expression in the
relative expression balance of the pairs of distinct spli-
cing variants (ASSET and additional AS) was evaluated
in both cell lines. We first calculated the expression
ratio from ASSET against the variant to each cDNA
template and then compared the expression ratio
between the C5.2 against Hb4a cell lines. For 3 out of 6
genes, a decrease in the expression balance of the
ASSET and additional AS variants was identified
between the tumor and normal cell lines (Figure 6;
Table 6). In more detail, the ASSETs corresponding to
SFRS9 [RefSeq: NM_003769.2] and FLNA [RefSeq:
NM_001456.3] genes were stably expressed between cell
lines, while the additional AS variants were more
expressed in the C5.2 compared to Hb4a cell line (fold
= 4 and 3.5, respectively) leading to a decrease of 4.84
(SFRS9)a n d4 . 7 8( FLNA) in the expression balance
between the splice variants (Table 6). The ASSET of the
TRIP6 gene [RefSeq: NM_003302.2] was more expressed
in the Hb4a than in the C5.2 (fold=4.6), whereas the
additional AS variant presented no expression differ-
ence. These results suggested that ERBB2-mediated
expression differently modulates the alternative splice
variants of the genes SFRS9, FLNA and TRIP6.F o rt h e
other 3 genes (RPS2, PTPLA and ALDH3A2), no differ-
ence in the expression balance of the AS variants
between the cell lines was observed (Table 6).
To confirm the alteration in the relative expression
balance of AS variants mediated by ERBB2 expression, a
different approach based on probe-specific ligation and
PCR amplification was applied [35]. In this strategy, 2
pairs of probes were designed for each gene, specifically
targeting the variants of interest (Figure 6). The expres-
sion balance difference was confirmed for all 3 genes
(FLNA, SFRS9 and TRIP6) visualized on the acrylamide
gel (Figure 6).
Discussion
The diversity of the human transcriptional repertoire
caused by AS has been extensively investigated [2,3],
and it is agreed that its regulation is an important
mechanism for physiological and pathological aspects of
cells. Moreover, AS is a major contributor to protein
diversity, which, in part, explains the high complexity of
mammals compared to much simpler organisms con-
taining a similar numbers of genes [5].
Table 3 Search for AS variants by comparison with
sequences from public databases
Presence of alternatively
spliced transcripts in
databases
No alternatively spliced
transcripts in databases
Lib_1 ATP1A1* CDC42SE1
ATP5A1 CDK5RAP2*
C6orf108 DDB2
CAMK2G EEF2
CD320 FARS2
CTSH GABARAP
ELF3 GNB3
FLNA* GRK6
GAPDH HDAC2
GNAS ITGB5*
GNPTAB MAN2A1
MAN1B1 OSBPL8
NAP1L1 PSMD6
PPIB PTPRA
RANBP1 188268
RPL28 RBM10*
RPL6 RNF149
RPS4X ROCK2
SETD2 RPL11
SFRS9* THSD1
STK25
UQCRC1
Lib_2 ALDH3A2* ACLY
AOF2* ASCC3L1
CCNB1 C7orf55
CREB3 COL7A1*
DNAJC10 DDEF1
FN1* DENND4C
INTS9 GDF9
MYO1C KIAA0090
RPS2* KIAA0152
RPS5 MRPL45
SEC61G PHF19
ST13 PTPLA*
RBMX
SGSM2
SLC4A2
TRIP6*
XPO1
Lib_1
&
Lib_2
CLTC* ATXN10
EIF4A3* INPP1
GSPT1* PAIP1
KRT18*
PSMC2*
*ASSETs selected for RT-PCR validation
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variability caused by this phenomenon, and one of the
most promising strategies is the use of AS enriched
cDNA libraries [25,26]. This strategy does not require
previous knowledge of the variants and permits an AS
transcriptome-wide analysis.
Deciphering of the human transcriptional repertoire
related to AS variability is an enormous contribution in
the comprehension of cancer and in the identification of
more precise molecular markers in cancer.
Here we described an AS enriched cDNA library
method by combining the use of trapping heteroduplex
and RNA amplification procedures. The methodology
was initially proposed by Watahiki and collaborators
[25] and was applied in this study with some modifica-
tions to favor its application in clinically-oriented cancer
studies, in which the availability of total RNA recovered
from tumor tissues is normally restrictive. Moreover, the
methodology established in this study is potentially
applicable to RNA purified from a homogenous tumor
cell population captured from a complex tissue by laser,
which produces transcriptional data more correlated
with the tumor cell.
Our strategy showed, in general, minimal artifacts in
the identification of ASSETs, since our validation rate
by RT-PCR was significantly high (94.5%). Moreover,
the fact that the great majority of the AS events found
in our AS enriched libraries were present in public data-
bases and that 100% of them harbor conserved splice
sites strengths the assumption that we have established
a robust methodology for identifying AS in a transcrip-
tome-wide format.
T h ef a c tt h a tw ec o u l dc o n f i r mb yR T - P C Rn o v e l
alternatively spliced transcripts for 2 genes to which no
AS variant was present in public databases is further
support that among the ASSETs with no confirmation
of AS events, a high frequency of prone additional AS
Table 4 Functional classification of genes within the statistically significant biological process categories
GO-ID Description Corrected p
value
Gene Symbol
Translation Elongation 1.67E+01 RPL6 RPL21 EEF2 RPL11 RPS4X RPS2 RPS5 RPL28
Intracellular Protein
Transport
4.21E+01 XPO1 CLTC GABARAP KRT18 YWHAH NUP62 ZFYVE16 KPNA6 RPL11 MRPL45 SEC61G SEC61A1 SRP9
Intracellular Transport 7.66E+01 XPO1 MYO1C CLTC GABARAP YWHAH KRT18 NUP62 ZFYVE16 SEC22B KPNA6 RPL11 RANBP1 GNAS
MRPL45 SRP9 SEC61G SEC61A1
Cellular Localization 2.55E+02 XPO1 MYO1C VIL2 CLTC GABARAP YWHAH KRT18 NUP62 ZFYVE16 SEC22B KPNA6 GNAS RPL11 RANBP1
MRPL45 SRP9 SEC61G SEC61A1
Establishment of
Localization in Cell
3.06E+02 XPO1 MYO1C CLTC GABARAP YWHAH KRT18 NUP62 ZFYVE16 SEC22B KPNA6 RPL11 RANBP1 GNAS
MRPL45 SRP9 SEC61G SEC61A1
Cellular Macromolecule
Metabolic Process
3.81E+02 PPP6C XPO1 UQCRC1 CAMK2G PTPLAD1 FARS2 DNAJC10 MAN1B1 RPS2 RPL6 PTPLA RPL11 PSMD6
DNAJA3 GLT25D1 STK25 ROCK2 PAIP1 PTPRA ZDHHC7 AXL MOBKL1A EEF2 RPS4X RPS5 RPL28 IFNAR1
CCNB1 MGAT1 ST13 SENP1 HDAC2 GSPT1 PPIB RPL21 PSMC2 DDB2 GRK6 MRPL45 CTSH
Protein Targeting 3.81E+02 XPO1 ZFYVE16 KPNA6 RPL11 GABARAP SRP9 SEC61G
Protein Localization 3.81E+02 XPO1 VIL2 CLTC GABARAP YWHAH KRT18 NUP62 ZFYVE16 SEC22B KPNA6 RPL11 GNAS MRPL45 SEC61G
SEC61A1 SRP9
Translation Elongation 3.81E+02 GSPT1 RPL6 RPL21 PAIP1 FARS2 EEF2 RPL11 RPS4X RPS2 MRPL45 RPS5 RPL28
Protein Transport 3.81E+02 XPO1 CLTC GABARAP YWHAH KRT18 NUP62 ZFYVE16 KPNA6 SEC22B RPL11 GNAS MRPL45 SEC61G
SEC61A1 SRP9
Establishment of Protein
Localization
3.81E+02 XPO1 CLTC GABARAP YWHAH KRT18 NUP62 ZFYVE16 KPNA6 SEC22B RPL11 GNAS MRPL45 SEC61G
SEC61A1 SRP9
Figure 4 Graphical view of GO Biological Process
overrepresented categories. The graphic is represented in a
hierarchical form. The yellow circles correspond to the categories
that were statistically significantly enriched.
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tion, is expected. The absence of amplification during
the validation process of additional AS transcripts for
two thirds of the selected genes suggests a significant
difference in the expression level of both variants with
consequent competition for the same pair of primers in
the PCR reaction, avoiding the amplification of low-
abundance AS transcripts.
The relatively high redundancy levels encountered in
both libraries (84.78% and 86.84%) were somewhat
expected. This number is similar to the redundancy
reported by Thill and collaborators [26]. In technical
terms, this problem can be bypassed by decreasing the
number of PCR cycles in the library construction, which
is relatively easy to control.
Another potential problem was that no additional
alternatively spliced transcripts were identified in
sequence data provided by enriched cDNA libraries
alone. This can be indicative of a problem caused by
using non-phosphorylated adaptors. In this situation,
only one strand (5’-3’) of these adaptors was ligated to
the 5’ end of the DpnII digested molecules that contains
a phosphate residue; the other strand (3’-5’)w a sn o t
ligated and, as a consequence, was disconnected from
the cDNA molecules at the denaturation step of PCR
and was consequently unable to be cloned and
sequenced. Usually this region is re-synthesized by poly-
merase at the first cycle of the PCR reaction through
annealing of complementary regions of cDNA mole-
cules, a process known as polymerase fill-in, also seen in
some cDNA library approaches [36,37]. However, in our
case where the strands of cDNA molecules are from dis-
tinct alternatively spliced transcripts, the fill-in process
is probably inefficient due to non-perfect annealing. To
avoid this problem, the use of phosphorylated adaptors
is a simple solution that would favor the representation
of both alternatively spliced transcripts that formed the
heteroduplex structure.
ERBB2,o rHER-2/neu,i sa no n c o g e n et h a ti so v e r -
expressed in 20-30% of human breast carcinomas and is
associated with poor prognosis, independent of the
lymph node status [38,39]. This marker is also associated
with chemo resistance to a range of anticancer drugs and
a positive response to herceptin [40,41]. Despite this
oncogene being most extensively investigated in clinical
and basic oncology, the ERBB2-mediated mechanism
involved in the transformation and progression of breast
tumors has not yet been totally elucidated.
In this study, we proposed to identify alternatively
spliced transcripts associated with breast tumors
that are under ERBB2 influence by constructing 2 AS-
enriched cDNA libraries using RNA sources representa-
tive of ERBB2 over-expression: the human breast cell
line C5.2 that was previously transfected with 4 copies
of full-length ERBB2 [42] and a pool of 5 breast carci-
noma samples, which demonstrate strong positivity in
ERBB2 immunostaining in tumor cell membranes [43].
For testing if the expression of ASSETs was regulated
by ERBB2-mediated expression, we evaluated the
ASSETs validated by RT-PCR in both cell lines, HB4a
and C5.2, the former with basal levels and the latter
with over-expression of ERBB2 mRNA [44]. Both cell
lines have been considered a model for the investigation
of ERBB2-mediated expression, since the only difference
between them is the insertion of 4 copies of full-length
ERBB2 in the C5.2 cell line [45,46]. For the ASSETs in
which we could identify an additional AS transcript by
RT-PCR, 50% of them (3 out of 6 - TRIP6, FLNA and
SFRS9) seemed to be influenced by ERBB2-mediated
expression, since differences in the relative expression
balance between both cell lines were observed.
Although the expression assessment of 2 or more AS
variants is a problematic issue concerning accurate
quantification the results presented here were confirmed
by an alternative methodology, which increased the
robustness of the data.
The microfluidic capillary electrophoresis-based strat-
egy relies on amplification of both variants in the same
reaction and could introduce bias due to amplification
competition between variants. However, this would be
expected to equally influence all reactions, independent
of the template used. The alternative strategy relies on
t h es p e c i f i cb i n d i n go fp r o b e su n d e rh i g h l ys t r i n g e n t
conditions, enabling the evaluation of each variant sepa-
rately, with high accuracy and is consequently very pro-
mising for AS expression assessment. The different
expression balance between both cell lines for 3 genes
confirmed by 2 different approaches suggests that these
genes transcribe AS variants, whose expression is differ-
ently influenced by ERBB2.
Table 5 RT-PCR validation
Library Origin Selected ASSETs ASSET validation Heteroduplex validation Cross-validation
Lib_1 65 2 4
Lib_2 77 4 7
Lib_1 & Lib_2 55 0 -
Library Origin: library where the ASSET was captured from; selected ASSETs: number of randomly selected ASSETs; ASSET validation: to confirm the presence of
the ASSET in the same RNA used for library construction; heteroduplex validation: amplification of alternatively spliced transcripts that could have participated in
the heteroduplex formation; and cross-validation: amplification of ASSETs specifically captured from one library using the cDNA template from the other library.
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Page 8 of 15Figure 5 Characterization of the novel AS variants identified. The scheme shows the genomic structure and protein domains of the known
and putative novel variants. The squares represent the exons, and the lines represent the introns. The dark regions represent the 5’and 3’
untranslated regions (UTR), the arrow represents the translational initiation site and the circles represent the stop codons. A – PTLA and
B – TRIP6.
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Page 9 of 15Figure 6 The influence of ERBB2-mediated expression on the regulation of AS variants. In the left panel, a schema of the microfluidic
capillary electrophoresis approach is shown. The exons are represented by numbered squares according to the exons involved in the AS events
for each gene. The black arrows represent the primers used for PCR amplification (PF - forward primer; PR - reverse primer). The
electropherogram represents the amplification of the AS variants for the Hb4a cell line (blue line) and for the C5.2 cell line (red line). The green
arrows indicates internal markers: LM (lower marker) and UM (upper marker). In the right panel, the probe-ligation approach is shown. Each pair
of probe is shown for each AS variant separately, with the corresponding PCR products on 8% acrylamide gel. M - 100 bp ladder. A - gene,
B-FLNA and C -TRIP6.
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Page 10 of 15FLNA is a member of the actin-binding protein family
that organizes actin filaments and is involved in numer-
ous cellular processes, especially development. Many
studies have reported the involvement of this protein in
carcinogenesis. Using melanoma cell lines lacking or
expressing FLNA, Fiori and collaborators [47] have
shown that this protein is an important regulator of
EGFR members (including ERBB2) that ensure efficient
ligand-mediated activation of these receptors and, con-
sequently, intracellular trafficking and degradation.
SFRS9 is a RNA-binding protein from the arginine/
serine-rich family that acts as a splicing factor regulating
constitutive splicing and also modulating the selection of
alternative splice sites. It has been suggested that this
protein acts downstream of the ERBB2 pathway, since
phosphorylation of SFRS9 was detected in ERBB2-over
expressing breast and ovarian cancer cells and was
reduced by monoclonal antibody Herceptin treatment.
Moreover, a putative role for SFRS9 in cell migration
was suggested, since migration was significantly retarded
following the depletion of SFRS9 transcripts in ovarian
cancer cell lines [48].
TRIP6 is a thyroid hormone receptor interactor that
localizes to focal adhesion sites and along actin stress
fibers [49,50]. This protein enhances lysophosphatidic
acid (LPA) -induced cell migration by directly binding
to the carboxyl-terminal tail of the LPA2 receptor
through its LIM domains [51]. Moreover, TRIP6 might
enhance cell migration by binding to PDZ domain of
MAGI-1b/PTEN destabilizing membrane b-catenin and
E-cadherin junctional complexes, promoting cell motility
[52].
The development of strategies to selectively represent
the AS transcripts repertoire, requiring small amounts
of total RNA, will be important for generating more cor-
related information between AS transcripts and specific
cell types and conditions in a transcriptome-wide
format.
In spite of using Sanger sequencing in this study, our
approach is completely suitable for using with next-gen-
eration sequencers [53], with the possibility of decreas-
ing the number of PCR cycles, and consequently the
redundancy level of the library; and assaying multiple
barcoded samples with high sequence coverage in a sin-
gle run. Finally, the use of next generation sequencers
w o u l dt r e m e n d o u s l ye x p a n dt h ea p p l i c a b i l i t yo fo u r
approach toward characterizing cancer cell transcrip-
tome diversity resulting from AS.
Conclusions
In this study we presented a method for exploring AS
from any RNA source that generates reliable AS data in
Table 6 Gene expression analysis under the influence of ERBB2 over-expression
Gene Symbol Cell line Variant Size (bp) Concentration (ng/ul) Normalized Concentration ASSET/ Variant C5.2/Hb4a
SFRS9 Hb4a ASSET 232 6.5 3.7 36.2 -4.8
variant 100 0.2 0.1
C5.2 ASSET 232 6.4 2.9 7.5
variant 100 0.9 0.4
FLNA Hb4a ASSET 500 24.9 14.1 95.7 -4.8
variant 377 0.3 0.2
C5.2 ASSET 500 23.0 10.4 20.0
variant 377 1.2 0.5
ALDH3A2 Hb4a ASSET 470 20.0 11.4 10.0 1.0
variant 610 2.0 1.1
C5.2 ASSET 470 24.6 11.0 10.3
variant 610 2.4 1.0
TRIP6 Hb4a ASSET 203 12.6 7.2 8.9 -3.4
variant 636 1.4 0.8
C5.2 ASSET 203 3.5 1.6 2.6
variant 636 1.3 0.6
PTPLA Hb4a ASSET 324 10.8 6.1 83.1 1.2
variant 456 0.1 0.1
C5.2 ASSET 324 16.8 7.5 98.4
variant 456 0.2 0.1
RPS2 Hb4a ASSET 187 13.7 7.8 1.4 1.1
variant 390 12.2 5.5
C5.2 ASSET 187 1.8 1.0 1.6
variant 390 1.4 0.6
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Page 11 of 15a transcriptome-wide format. Additionally, our data
identified AS transcript candidates whose expression
was influenced by ERBB2-mediated expression and can
be tested as molecular markers for breast cancer. The
association of such methodology with deep sequencing
may be helpful for completely deciphering the cancer
cell transcriptome and finding more precise molecular
markers.
Methods
Samples
The human breast cell line C5.2 is derived from normal
luminal cells transfected with four copies of the full-
length ERBB2 cDNA (HER-2/neu) gene presenting
tumor characteristics [42]. Cells were maintained in
RPMI medium supplemented with 100 ml/l fetal bovine
serum (FBS), 5 µg/ml insulin, 5 µg/ml hydrocortisone
and 1 mmol/l L-glutamine in a humidified incubator
containing 50 ml/l CO2 at 37°C. The medium was chan-
ged every 2-3 days, and after 10 days the total RNA was
extracted using a CsCl gradient [54]. The yield of
extracted total RNA was determined with a Kontron
810 spectrophotometer GeneQuant pro (GE Healthcare
Life Sciences), and the integrity was also verified by
electrophoresis through 1% agarose gel upon visualiza-
tion with ethidium bromide.
RNA samples from 5 ductal breast carcinoma samples
used in this study were provided by the biorepository
bank from A.C. Camargo Hospital (São Paulo, Brazil).
These samples were positive for ERBB2 through immu-
nohistochemistry analysis (Table 6), according to the
following criteria: weak to moderate complete mem-
brane staining in > 10% of tumor cells or strong com-
plete membrane staining in > 30% of tumor cells.
Alternative splicing enriched cDNA library construction
RNA amplification and double strand cDNA synthesis
For first strand cDNA synthesis, total RNA was incu-
bated with 0.75 µg oligo dT containing the T7 RNA
polymerase site (5’AAACGACGGCCAGTGAATTG-
TAATACGACTCACTATAGGCGCT(24)’3’)a t7 0 ° Cf o r
10 minutes. The reaction was performed by adding 1X
first strand buffer, 0.01 M DTT (Dithiothreitol), 40 U of
RNasin (Promega Corporation), 1 mM dNTP (GE
Healthcare Life Sciences), 1 µg of Template Switch (TS)
DNA Oligo (5’AAGCAGTGGTAACAACGCAGAG-
TACGCGGG 3’)a n d4 0 0Uo fS u p e r S c r i p tI I( I n v i t r o -
gen Life Technologies) in a total volume of 20 µl. The
reaction was incubated for 120 min at 42°C. For the sec-
ond strand synthesis, the Advantage® cDNA PCR Kit
(Clontech) was used as follows: 5X cDNA PCR Reaction
Buffer, 1 mM dNTP Mix, 5X Advantage cDNA Poly-
merase Mix, 1.4 U of RNase H (Invitrogen Life
Technologies) in a final volume of 100 µl. The reaction
was incubated at 37°C for 10 min, 94°C for 3 min, 65°C
for 5 min. and 75°C for 30 min. The stop reaction
including 0.25 M of NaOH and 0.5 mM EDTA was
added, followed by incubation at 65°C for 10 min. The
dscDNA was purified by phenol:chloroform:isoamylic
alcohol (25:24:1) pH 8.0 extraction followed by Micro-
con YM-100 Centrifugal Filter Unit (Millipore).
Double-strand cDNA was in vitro transcribed into
RNA with RiboMAX
™ Large Scale RNA Production Sys-
tems (Promega Corporation) as follows: 1X buffer, 3 µM
rNTP and 2.5 µl Enzyme T7 Mix. The reaction was
incubated at 37°C for 6 hours. Amplified RNA (aRNA)
was purified by TRIzol® Reagent (Sigma Aldrich
Corporation).
After purification, aRNA was used for double-stranded
cDNA synthesis as described above using 1 µg of TS-
oligo for the first strand synthesis and 0.5 µg oligo dT
(24) for the second strand synthesis.
Denaturation and renaturation
Double-stranded cDNA molecules were heated at 96°C
for 20 min and incubated at 42°C for 24 hours in a mix-
ture of 0.2% SDS, 0.5 M NaCl, 0.05 M Tris-HCl pH 7.5
and 30% formamide.
Exonuclease VII cleavage
Exonuclease VII (USB Corporation) cleavage was per-
formed in 70 mM Tris-HCI, pH 8.0; 8 mM EDTA, pH
8.0; 10 mM 2-mercaptoethanol; 50 µg/ml BSA and 0.2
U of the enzyme and incubated at 37°C for 30 min. The
enzyme was inactivated at 95°C for 10 min.
DpnII digestion
Fifteen units of the restriction enzyme II (New England
Biolabs) was used for each 500 ng of cDNA in 1X buf-
fer. The reaction was incubated at 37°C for 3 hours.
Heteroduplex molecule trapping by biotin-streptavidin
The cDNA sample was incubated with 100 pmoles of
random 25-mer oligonucleotide biotinilated at the 5’
end in 6X SSC and 0.1% SDS at 65 °C for 16 hours.
This mixture was incubated with 1 mg streptavidin
magnetic particles (F. Hoffmann-La Roche Ltd.) and 300
μl TEN100 binding buffer (10 mM Tris-HCl; 1 mM
EDTA; 100 mM NaCl, pH 7.5) for 30 min at room tem-
perature. The tube was applied to a magnetic separator,
and the supernatant was removed and incubated with
another aliquot of streptavidin magnetic particle for a
second round of purification. Both aliquots of magnetic
particles coupled to heteroduplex molecules by the bio-
tinilated random oligonucleotide were mixed and
washed 3 times with TEN100 washing buffer (10 mM
Tris-HCl; 1 mM EDTA; 1 M NaCl, pH 7.5). The cDNA
Ferreira et al. BMC Genomics 2010, 11(Suppl 5):S4
http://www.biomedcentral.com/1471-2164/11/S5/S4
Page 12 of 15molecules were then eluted from the magnetic particles
by adding 6 M guanidine-HCl and purified by a phenol:
chloroform: isoamylic alcohol pH 8.0 extraction.
Ligation of XDPN12 and XDPN14 adaptors
The adaptors were commercially synthesized and con-
tained four bases complementary to the cleavage site of
the DpnII enzyme. First, the cDNA molecules were
mixed with 1X T4 Ligase Buffer, 400 pmols XDPN12
(5’GATCTCTCGAGT3’) and 400 pmols XDPN14
(5’CTGATCACTCGAGA3’)a n di n c u b a t e da t5 5 ° Cf o r
1 min. Next, the temperature was decreased from 54°C
to 28°C at a rate of 2°C every 2 min and from 28°C to
14°C at a rate of 2°C every 4 min to favor a perfect
annealing of the oligonucleotides. At last, 2000 units of
T4 DNA ligase (Invitrogen Life Technologies) were
added, and the reaction was incubated at 14°C for
16 hours. The reaction was purified with a Microcon
YM-100 Centrifugal Filter Unit (Millipore).
Polymerase chain reaction
The RT-PCR reaction was carried out in 1X buffer, 0.1
mM dNTP, 1.5 mM MgCl2, 200 pmols XDPN18 oligo-
nucleotide (5’CTGATCACTCGAGAGATC3’), 2 units
GoTaq® DNA Polymerase (Promega Corporation) and
10 µl of purified cDNA in a total volume of 20 µl. The
reaction was incubated at 95°C for 4 min followed by 35
cycles of 95°C for 45 s, 58°C for 1 min and 72°C for 4
min and a final extension at 72° for 7 min.
Cloning and sequencing
PCR products were inserted into T/A plasmid vector
pTZ57R/T using the InsT/Aclone PCR Product Cloning
Kit (Fermentas Life Sciences), following the manufac-
turer’s recommendations, in a total volume of 10 µl. The
ligation was performed at 22°C for 16 hours. The ligation
was dialyzed for 20 min in 0.025 µM nitrocellulose mem-
brane (Millipore), and 3 µl was used for transformation
in DH10B E. coli cells by electroporation (2.5 KV, 25
μFD, 200 OHMS). The clone inserts were sequenced
with ABI Prism 3100 (Applied Biosystems). The sequen-
cing reaction was performed with M13 reverse primer
(5’GTCATAGCTGTTTCCTG3’) and BigDye Terminator
v3.1 cycle sequencing kit (Applied Biosystems), following
the manufacturer’s recommendations.
Bioinformatics analysis
The sequences were automatically analyzed, and regions
corresponding to vector sequences were trimmed. The
quality control was performed in 20 bp windows, where
only windows containing at least 15 bp with a Phrep
quality score ≥ 20 were considered.
The sequences of each library were clustered individu-
ally using the CAP3 program, allowing estimation of
library’s redundancy. The consensus sequences were
first aligned against the human genome (NCBI build
#36.1) using BLAT [29]. Second, to improve the quality
and specificity of alignment the best hit of each
sequence in the genome was selected, and realigned
using Sim4 [30]. Third, sequences showing identity ≥
93% and sequence coverage (percentage of sequence
length aligned) ≥ 55% were considered. Lastly, the
sequences were clustered with ESTs from dbEST
(8,133,299 sequences), mRNAs (244,284 sequences) and
RefSeqs (26,040 sequences) downloaded from UCSC
(September 2007) (see Galante [55] for more details).
RT-PCR validation
The primers for splice variant validation were designed
at the extremities of the ASSET sequence. Twenty nano-
grams of cDNA from both the total RNA from the C5.2
cell line and the pool of breast cancer samples were
used to validate the ASSETs from Lib_1 and Lib_2,
respectively. The PCR reaction was performed in a total
volume of 20 μl by mixing 1 X reaction buffer (Invitro-
gen Life Technologies), 2.5 mM MgCl2 (Invitrogen Life
Technologies), 0.2 mM dNTP (Amersham Biosciences),
10 pmoles of each primer and 1 unit Taq Platinum
(Invitrogen Life Technologies). PCR reactions were per-
formed with 40 cycles at 95°C for 30 sec, 60°C for 30
sec and 72°C for 30 sec, followed by a final extension at
72°C for 7 min. Amplification products were visualized
on a 8% acrylamide gel and subsequently sequenced by
ABI3130.
ERBB2 influence on relative expression
For verifying the ERBB2 influence on gene expression,
all ASSETs were amplified using the C5.2 cell line and
also the Hb4a cell line, which is a human mammary
luminal epithelial cell line. The PCR products were
quantified through capillary microfluidic electrophoresis
(LabChip GX – Caliper Lifesciences). The expression of
the GAPDH g e n ew a su s e da san o r m a l i z a t i o nf a c t o r .
The expression ratio was determined by the normalized
value of C5.2 divided by the normalized value of Hb4a
for each ASSET. Genes were considered to be differently
expressed between cell lines for ratios ≥|2|. The differ-
ently expressed genes were analyzed in a group of
tumor and normal breast samples through a strategy
based on specific-probe ligation. The left and right
probes were targeted against specific exon junctions of
each variant of a gene. The left probe contained at its 5’
end a recognition sequence of the forward PCR primer
(GGGTAGGCTAAGGGTAGGA) followed by a stuffer
sequence of 38 nucleotides (CCGTTGCCAGTCTGCT-
CAGACCTCCCTCGCGCCATCAG), and the right
probe was phosphorylated at its 5’ end and contained a
recognition sequence of the reverse PCR primer
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Page 13 of 15(TCTAGATTGGATCTTGCTGGCAC) at its 3’ end. A
specific RT primer designed downstream of the probe
target sequence was used for cDNA synthesis. The
probes were hybridized to pre-heated cDNA from Hb4a
and C5.2 at 60°C overnight, and only the probes specifi-
cally hybridized to their target sequences were con-
nected by T4 DNA ligase, resulting in one unique
probe. As a negative control, ligation and hybridization
were performed in the absence of any template for all
pairs of probes. The unique probes were PCR amplified.
Amplification products were analyzed on 8% acrylamide
gel. (Additional file 1).
Additional material
Additional File 1: Gene expression analysis under the influence of
ERBB2 over-expression.
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